Medical oncology
Service
Consorci Sanitari de Terrassa
Terrassa, EspañaPublications in collaboration with researchers from Consorci Sanitari de Terrassa (11)
2024
-
Cross-sectional and longitudinal associations of adherence to WCRF/AICR cancer prevention recommendations with health-related quality of life in breast cancer survivors. Health-EpiGEICAM study
Journal of Nutrition, Health and Aging, Vol. 28, Núm. 8
2022
-
Clinical and Sociodemographic Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Recommendations in Breast Cancer Survivors—Health-EpiGEICAM Study
Cancers, Vol. 14, Núm. 19
-
Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics
BMC Cancer, Vol. 22, Núm. 1
2021
-
Electronic health records and patient registries in medical oncology departments in Spain
Clinical and Translational Oncology, Vol. 23, Núm. 10, pp. 2099-2108
-
Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data
BMC Cancer, Vol. 21, Núm. 1
2020
-
Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study
Scientific Reports, Vol. 10, Núm. 1
2019
-
Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study
Scientific Reports, Vol. 9, Núm. 1
2017
-
A PAM50-based chemoendocrine score for hormone receptor-positive breast cancer with an intermediate risk of relapse
Clinical Cancer Research, Vol. 23, Núm. 12, pp. 3035-3044
2014
-
Predicting response and survival in chemotherapy-treated triple-negative breast cancer
British Journal of Cancer, Vol. 111, Núm. 8, pp. 1532-1541
2012
-
Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: Results from the GEICAM/2006-03, a multicenter, randomized, phase-II study
Annals of Oncology, Vol. 23, Núm. 12, pp. 3069-3074
2010
-
Adjuvant docetaxel for high-risk, node-negative breast cancer
New England Journal of Medicine, Vol. 363, Núm. 23, pp. 2200-2210